OncoMatch/Clinical Trials/NCT06778031
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Is NCT06778031 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-A1811 and SHR-1316 for her2-positive locally advanced or metastatic biliary tract cancer.
Treatment: SHR-A1811 · SHR-1316 · SHR-8068 — This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: local antitumor therapy
Local antitumor therapy was received within 4 weeks prior to initiation of treatment
Lab requirements
Blood counts
The main organ function is normal, in line with the program requirements
Kidney function
The main organ function is normal, in line with the program requirements
Liver function
The main organ function is normal, in line with the program requirements
The main organ function is normal, in line with the program requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify